Ipilimumab-Induced Neutropenia in Melanoma

Ipilimumab-Induced Neutropenia in Melanoma

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...

Full description

Bibliographic Details
Main Authors: Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD
Format: Article
Language:English
Published: SAGE Publishing 2016-08-01
Series:Journal of Investigative Medicine High Impact Case Reports
Online Access:https://doi.org/10.1177/2324709616661835
id doaj-94076e5cf7b64fdca7819f6dc17f5227
record_format Article
spelling doaj-94076e5cf7b64fdca7819f6dc17f52272020-11-25T03:41:16ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962016-08-01410.1177/232470961666183510.1177_2324709616661835Ipilimumab-Induced Neutropenia in MelanomaMakiko Ban-Hoefen MD0Richard Burack MD1Lynn Sievert NP2Deepak Sahasrabudhe MD3University of Rochester Medical Center, Rochester, NY, USAUniversity of Rochester Medical Center, Rochester, NY, USAUniversity of Rochester Medical Center, Rochester, NY, USAUniversity of Rochester Medical Center, Rochester, NY, USAIpilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.https://doi.org/10.1177/2324709616661835
collection DOAJ
language English
format Article
sources DOAJ
author Makiko Ban-Hoefen MD
Richard Burack MD
Lynn Sievert NP
Deepak Sahasrabudhe MD
spellingShingle Makiko Ban-Hoefen MD
Richard Burack MD
Lynn Sievert NP
Deepak Sahasrabudhe MD
Ipilimumab-Induced Neutropenia in Melanoma
Journal of Investigative Medicine High Impact Case Reports
author_facet Makiko Ban-Hoefen MD
Richard Burack MD
Lynn Sievert NP
Deepak Sahasrabudhe MD
author_sort Makiko Ban-Hoefen MD
title Ipilimumab-Induced Neutropenia in Melanoma
title_short Ipilimumab-Induced Neutropenia in Melanoma
title_full Ipilimumab-Induced Neutropenia in Melanoma
title_fullStr Ipilimumab-Induced Neutropenia in Melanoma
title_full_unstemmed Ipilimumab-Induced Neutropenia in Melanoma
title_sort ipilimumab-induced neutropenia in melanoma
publisher SAGE Publishing
series Journal of Investigative Medicine High Impact Case Reports
issn 2324-7096
publishDate 2016-08-01
description Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.
url https://doi.org/10.1177/2324709616661835
work_keys_str_mv AT makikobanhoefenmd ipilimumabinducedneutropeniainmelanoma
AT richardburackmd ipilimumabinducedneutropeniainmelanoma
AT lynnsievertnp ipilimumabinducedneutropeniainmelanoma
AT deepaksahasrabudhemd ipilimumabinducedneutropeniainmelanoma
_version_ 1724530733617250304

Similar Items